190 related articles for article (PubMed ID: 11082717)
1. [Platinum salts: cytotoxic mechanisms of action, mechanisms of resistance of cancer cells, interactions with ionizing radiation, specificity of carboplatin].
Rixe O
Bull Cancer; 2000 Aug; 87 Spec No():7-15. PubMed ID: 11082717
[TBL] [Abstract][Full Text] [Related]
2. Analysis of cytotoxicities of platinum compounds.
Goodisman J; Hagrman D; Tacka KA; Souid AK
Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101
[TBL] [Abstract][Full Text] [Related]
3. Insights into mechanisms of cisplatin resistance and potential for its clinical reversal.
Gosland M; Lum B; Schimmelpfennig J; Baker J; Doukas M
Pharmacotherapy; 1996; 16(1):16-39. PubMed ID: 8700790
[TBL] [Abstract][Full Text] [Related]
4. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.
Reardon JT; Vaisman A; Chaney SG; Sancar A
Cancer Res; 1999 Aug; 59(16):3968-71. PubMed ID: 10463593
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin and platinum drugs at the molecular level. (Review).
Boulikas T; Vougiouka M
Oncol Rep; 2003; 10(6):1663-82. PubMed ID: 14534679
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of resistance to cisplatin and carboplatin.
Stewart DJ
Crit Rev Oncol Hematol; 2007 Jul; 63(1):12-31. PubMed ID: 17336087
[TBL] [Abstract][Full Text] [Related]
7. Preclinical perspectives on the use of platinum compounds in cancer chemotherapy.
Farrell NP
Semin Oncol; 2004 Dec; 31(6 Suppl 14):1-9. PubMed ID: 15726528
[TBL] [Abstract][Full Text] [Related]
8. Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase.
Deng HB; Adikari M; Parekh HK; Simpkins H
Cancer Chemother Pharmacol; 2004 Oct; 54(4):301-7. PubMed ID: 15138708
[TBL] [Abstract][Full Text] [Related]
9. Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin.
Mizutani Y; Nakao M; Ogawa O; Yoshida O; Bonavida B; Miki T
J Urol; 2001 Jan; 165(1):263-70. PubMed ID: 11125422
[TBL] [Abstract][Full Text] [Related]
10. Effects of a piperidine ligand on DNA modification by antitumor cisplatin analogues.
Kasparkova J; Novakova O; Najajreh Y; Gibson D; Perez JM; Brabec V
Chem Res Toxicol; 2003 Nov; 16(11):1424-32. PubMed ID: 14615968
[TBL] [Abstract][Full Text] [Related]
11. Cellular sensitization to cisplatin and carboplatin with decreased removal of platinum-DNA adduct by glucose-regulated stress.
Yamada M; Tomida A; Yun J; Cai B; Yoshikawa H; Taketani Y; Tsuruo T
Cancer Chemother Pharmacol; 1999; 44(1):59-64. PubMed ID: 10367750
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance.
Rudin CM; Yang Z; Schumaker LM; VanderWeele DJ; Newkirk K; Egorin MJ; Zuhowski EG; Cullen KJ
Cancer Res; 2003 Jan; 63(2):312-8. PubMed ID: 12543781
[TBL] [Abstract][Full Text] [Related]
13. Cross-resistance of platinum derivatives in H-1R, a cisplatin-resistant cell line.
Negoro K; Yamano Y; Nakashima D; Saito K; Nakatani K; Shiiba M; Bukawa H; Yokoe H; Uzawa K; Wada T; Tanzawa H; Fujita S
Oncol Rep; 2009 Feb; 21(2):443-9. PubMed ID: 19148521
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents.
Youn CK; Kim MH; Cho HJ; Kim HB; Chang IY; Chung MH; You HJ
Cancer Res; 2004 Jul; 64(14):4849-57. PubMed ID: 15256455
[TBL] [Abstract][Full Text] [Related]
15. A pleiotropic defect reducing drug accumulation in cisplatin-resistant cells.
Liang XJ; Shen DW; Gottesman MM
J Inorg Biochem; 2004 Oct; 98(10):1599-606. PubMed ID: 15458822
[TBL] [Abstract][Full Text] [Related]
16. Understanding cisplatin resistance using cellular models.
Stordal B; Davey M
IUBMB Life; 2007 Nov; 59(11):696-9. PubMed ID: 17885832
[TBL] [Abstract][Full Text] [Related]
17. High accumulation of platinum-DNA adducts in strial marginal cells of the cochlea is an early event in cisplatin but not carboplatin ototoxicity.
Thomas JP; Lautermann J; Liedert B; Seiler F; Thomale J
Mol Pharmacol; 2006 Jul; 70(1):23-9. PubMed ID: 16569706
[TBL] [Abstract][Full Text] [Related]
18. P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin.
Lin X; Ramamurthi K; Mishima M; Kondo A; Christen RD; Howell SB
Cancer Res; 2001 Feb; 61(4):1508-16. PubMed ID: 11245458
[TBL] [Abstract][Full Text] [Related]
19. Formation of platinum-DNA adducts in pediatric patients receiving carboplatin.
Tonda ME; Murry DJ; Rodman JH
Pharmacotherapy; 1996; 16(4):631-7. PubMed ID: 8840369
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis.
Yang Z; Schumaker LM; Egorin MJ; Zuhowski EG; Guo Z; Cullen KJ
Clin Cancer Res; 2006 Oct; 12(19):5817-25. PubMed ID: 17020989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
